Physician profile
Emily Murphy
NPI 1578192050
$2,979.01
in general payments reported to CMS, 2019-2025
19 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,692 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,969 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.36 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $335.49 | 2024-2025 | |
| Pfizer INC. | $329.96 | 2024-2025 | |
| Leo Pharma INC. | $328.91 | 2024-2025 | Anzupgo, Adbry |
| Regeneron Healthcare Solutions, INC. | $244.64 | 2024-2025 | Dupixent |
| Genzyme Corporation | $224.93 | 2024-2025 | |
| Janssen Biotech, INC. | $216.50 | 2024-2025 | Tremfya |
| Ucb, INC. | $173.04 | 2024-2025 | Bimzelx |
| Kyowa Kirin, INC. | $156.65 | 2024 | Poteligeo |
| E.R. Squibb & Sons, L.L.C. | $147.23 | 2024-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.95 | 2024-2025 | Spevigo |
| Almirall LLC | $133.96 | 2024 | Klisyri |
| Dermavant Sciences, INC. | $129.11 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $126.14 | 2024 | |
| Incyte Corporation | $98.66 | 2024-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $71.04 | 2024-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $44.02 | 2024-2025 | Valchlor |
| Springworks Therapeutics, INC. | $35.04 | 2025 | Gomekli |
| Lilly USA, LLC | $22.91 | 2024 | Olumiant, Taltz |
| Astrazeneca Pharmaceuticals Lp | $21.83 | 2025 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.